Search Results - "Beuvery, E Coen"

Refine Results
  1. 1

    Scale-up for bulk production of vaccine against meningococcal disease by Baart, Gino J.E, de Jong, Govert, Philippi, Marvin, Riet, Klaas van’t, van der Pol, Leo A, Beuvery, E. Coen, Tramper, Johannes, Martens, Dirk E

    Published in Vaccine (21-08-2007)
    “…Abstract At the Netherlands Vaccine Institute (NVI) a vaccine against Neisseria meningitidis serogroup B organisms based on different porA subtypes contained…”
    Get full text
    Journal Article
  2. 2

    Evaluation of a critical process parameter: Oxygen limitation during cultivation has a fully reversible effect on gene expression of Bordetella pertussis by Streefland, Mathieu, van de Waterbeemd, Bas, Kint, Joeri, van der Pol, Leo A, Beuvery, E. Coen, Tramper, Johannes, Martens, Dirk E

    Published in Biotechnology and bioengineering (2009)
    “…Modern (bio)pharmaceutical process development requires thorough investigation of all process parameters that are critical to product quality. The impact of a…”
    Get full text
    Journal Article
  3. 3

    Modeling Neisseria meningitidis metabolism: from genome to metabolic fluxes by Baart, Gino J E, Zomer, Bert, de Haan, Alex, van der Pol, Leo A, Beuvery, E Coen, Tramper, Johannes, Martens, Dirk E

    Published in Genome Biology (06-07-2007)
    “…Neisseria meningitidis is a human pathogen that can infect diverse sites within the human host. The major diseases caused by N. meningitidis are responsible…”
    Get full text
    Journal Article
  4. 4

    Modeling Neisseria meningitidis B metabolism at different specific growth rates by Baart, Gino J.E, Willemsen, Marieke, Khatami, Elnaz, de Haan, Alex, Zomer, Bert, Beuvery, E. Coen, Tramper, Johannes, Martens, Dirk E

    Published in Biotechnology and bioengineering (01-12-2008)
    “…Neisseria meningitidis is a human pathogen that can infect diverse sites within the human host. The major diseases caused by N. meningitidis are responsible…”
    Get full text
    Journal Article
  5. 5

    PAT for vaccines: The first stage of PAT implementation for development of a well-defined whole-cell vaccine against whooping cough disease by Streefland, Mathieu, van de Waterbeemd, Bas, Happé, Hester, van der Pol, Leo A, Beuvery, E. Coen, Tramper, Johannes, Martens, Dirk E

    Published in Vaccine (20-04-2007)
    “…Abstract Since variation in process time and process output is commonly accepted to be inevitable for biological processes, application of Process Analytical…”
    Get full text
    Journal Article Conference Proceeding
  6. 6

    Manufacturing Vaccines: An Illustration of Using PAT Tools for Controlling the Cultivation of Bordetella pertussis by van Sprang, Eric N. M., Streefland, Mathieu, Ramaker, Henk-Jan, van der Pol, Leo A., Beuvery, E. Coen, Smilde, Age. K.

    Published in Quality engineering (29-10-2007)
    “…An illustration of the operational consistency of the upstream part of a biopharmaceutical process is given. For this purpose four batch cultivations of…”
    Get full text
    Journal Article
  7. 7

    Preparation and application of a fluorescein-labeled peptide for determining the affinity constant of a monoclonal antibody-hapten complex by fluorescence polarization by Jiskoot, W, Hoogerhout, P, Beuvery, E C, Herron, J N, Crommelin, D J

    Published in Analytical biochemistry (01-08-1991)
    “…A simple and rapid method for determining the affinity constant of a monoclonal antibody-peptide complex under equilibrium conditions is presented. A peptide…”
    Get more information
    Journal Article
  8. 8

    Preparation of clinical grade monoclonal antibodies from serum-containing cell culture supernatants by Jiskoot, W, Van Hertrooij, J J, Hoven, A M, Klein Gebbinck, J W, Van der Velden-de Groot, T, Crommelin, D J, Beuvery, E C

    Published in Journal of immunological methods (25-04-1991)
    “…Three mouse monoclonal antibodies (Mab), RIV6, MN12, and WT31, were purified from cell culture supernatants containing foetal bovine serum (FBS) by two-step…”
    Get more information
    Journal Article
  9. 9

    Analysis of glycoforms present in two mouse IgG2a monoclonal antibody preparations by Coco-Martin, J M, Brunink, F, van der Velden-de Groot, T A, Beuvery, E C

    Published in Journal of immunological methods (05-11-1992)
    “…Lectins have been used for the determination of the oligosaccharide structures expressed by two monoclonal IgG antibodies, MN12 and RIV6. Dot blot experiments…”
    Get more information
    Journal Article
  10. 10
  11. 11

    Two-step purification of a murine monoclonal antibody intended for therapeutic application in man. Optimisation of purification conditions and scaling up by Jiskoot, W, Van Hertrooij, J J, Klein Gebbinck, J W, Van der Velden-de Groot, T, Crommelin, D J, Beuvery, E C

    Published in Journal of immunological methods (13-11-1989)
    “…The murine hybridoma cell line WT31, which produces a monoclonal antibody (Mab) of the IgG1 isotype with specificity for the human T cell receptor, was grown…”
    Get more information
    Journal Article
  12. 12

    Viability measurements of hybridoma cells in suspension cultures by COCO-MARTIN, J. M, OBERINK, J. W, VAN DER VELDEN-DE GROOT, T. A. M, COEN BEUVERY, E

    Published in Cytotechnology (Dordrecht) (01-01-1992)
    “…Several methods were applied to determine the viability of hybridoma cells in suspension. These methods include dye inclusion and exclusion assays such as the…”
    Get full text
    Journal Article
  13. 13

    Purification and stabilisation of a poorly soluble mouse IgG3 monoclonal antibody by Jiskoot, W, Hoven, A M, De Koning, A A, Leerling, M F, Reubsaet, C H, Crommelin, D J, Beuvery, E C

    Published in Journal of immunological methods (25-04-1991)
    “…The anti-T cell monoclonal antibody (Mab) RIV9 (mouse IgG3, kappa) has been developed for clinical use in the treatment of allograft rejection. In order to…”
    Get more information
    Journal Article
  14. 14

    The potential of flow cytometric analysis for the characterization of hybridoma cells in suspension cultures by COCO-MARTIN, J. M, OBERINK, J. W, VAN DER VELDEN-DE GROOT, T. A. M, COEN BEUVERY, E

    Published in Cytotechnology (Dordrecht) (01-01-1992)
    “…Flow cytometric (FC) analysis was applied to determine changes at cellular level during the cultivation of hybridoma cell line MN12 in a suspension batch…”
    Get full text
    Journal Article
  15. 15

    Immunological evaluation of meningococcal group C polysaccharide-tetanus toxoid conjugate in mice by COEN BEUVERY, E, VAN DELFT, R. W, MIEDEMA, F, KANHAI, V, NAGEL, J

    Published in Infection and Immunity (01-08-1983)
    “…Classifications Services IAI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
  16. 16

    Immunoglobulin M and G antibody responses and persistence of these antibodies in adults after vaccination with a combined meningococcal group A and group C polysaccharide vaccine by Beuvery, E C, Leussink, A B, Van Delft, R W, Tiesjema, R H, Nagel, J

    Published in Infection and Immunity (01-08-1982)
    “…Classifications Services IAI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
  17. 17

    Single shot with tetanus toxoid in biodegradable microspheres protects mice despite acid-induced denaturation of the antigen by Kersten, Gideon F.A., Donders, Dian, Akkermans, Arnoud, Beuvery, E.Coen

    Published in Vaccine (01-12-1996)
    “…Tetanus toxoid encapsulated in microspheres consisting of biodegradable polyesters, prepared by four different manufacturers were evaluated with respect to…”
    Get full text
    Journal Article
  18. 18

    Randomised, controlled trial with the trypsin-modified inactivated poliovirus vaccine: assessment of intestinal immunity with live challenge virus by Piirainen, Liisa, Stenvik, Mirja, Roivainen, Merja, Eskola, Juhani, Beuvery, E.Coen, Hovi, Tapani

    Published in Vaccine (05-03-1999)
    “…The enhanced potency inactivated poliovirus vaccine (E-IPV) was modified to contain trypsin-treated type 3 poliovirus (PV3), strain Saukett, as the type 3…”
    Get full text
    Journal Article
  19. 19

    On the structure of immune-stimulating saponin-lipid complexes (iscoms) by Kersten, G F, Spiekstra, A, Beuvery, E C, Crommelin, D J

    Published in Biochimica et biophysica acta (25-02-1991)
    “…Immune-stimulating complexes (iscoms) are stable complexes of cholesterol, phospholipid and Quil A, a triterpene saponin mixture in the size range from 40 to…”
    Get more information
    Journal Article
  20. 20

    Analytical approaches to the study of monoclonal antibody stability by JISKOOT, W, BEUVERY, E. C, DE KONING, A. A. M, HERRON, J. N, CROMMELIN, D. J. A

    Published in Pharmaceutical research (01-12-1990)
    “…The stability of two purified monoclonal antibodies, MN12 and WT31, was investigated. The monoclonal antibodies were incubated for 32 days at different pH…”
    Get full text
    Journal Article